Health Economics›Colorectal cancer›Advanced or metastatic disease second-line therapy

Advanced or metastatic disease second-line therapy

Colorectal cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FOLFIRI and Ziv-aflibercept Variant #01	—	R 546 974	14d	6.9 mo	13.5 mo	16	R 8 751 587 PFS proxy	2
FOLFIRI and Ramucirumab Variant #01	—	R 50 669	14d	—	13.3 mo	—	—	1
CAPIRI-Bev Variant #01	—	R 16 013	21d	—	16.8 mo	—	—	1
CapeOx and Erlotinib Variant #01	—	R 12 568	21d	—	—	—	—	—
FOLFIRI and Bevacizumab Variant #01	—	R 12 367	14d	6.8 mo	13.3 mo	15	R 185 512 PFS proxy	3
mFOLFOX6-B Variant #01	—	R 12 127	14d	6.8 mo	—	15	R 181 908 PFS proxy	1
FOLFIRI and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 11 410	14d	6.1 mo	15.4 mo	14	R 159 744 PFS proxy	2
FOLFIRI Variant #05	—	R 2 826	14d	5.0 mo	12.1 mo	11	R 31 090 PFS proxy	8
mFOLFOX6 Variant #02	—	R 2 466	14d	5.0 mo	—	11	R 27 131 PFS proxy	1
CapeOx Variant #01	—	R 2 384	21d	4.7 mo	—	7	R 16 689 PFS proxy	1
IROX Variant #01	—	R 2 196	21d	—	13.4 mo	—	—	1
FOLFOX4 Variant #01	—	R 2 064	14d	4.8 mo	11.9 mo	11	R 22 700 PFS proxy	4
FOLFIRI (L-Leucovorin) Variant #01 Partial	—	R 1 869	14d	—	15.4 mo	—	—	1
IRI-S Variant #01 Partial	—	R 1 603	28d	5.8 mo	—	7	R 11 222 PFS proxy	1
FULV Variant #01	—	R 1 466	35d	~6.2 mo	~13.2 mo	~6	~R 8 795 PFS proxy · indirect	6
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	8.5 mo	—	—	—
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	10.9 mo	—	—	4
CAPIRI N/A - secondary systemic drug	—	R 1	21d	—	16.8 mo	—	—	1

18 of 18 regimens shown